Méta-analyses en réseau : Comparaisons indirectes et directes des traitements (CT, CEESP)

 

Lire la suite

 

Modélisation médico-économique : Efficience, impact budgétaire (CEESP, CEPS)

 

Lire la suite

 

Etudes médico-économiques en vie réelle (SNDS, cohortes)

 

Lire la suite

 

 

Etudes sur Open data directement accessibles (openDAMIR, openMEDIC, etc.), data science, réseaux sociaux

 

Lire la suite

 

Etudes économiques et statistiques

Statésia est un bureau d’études spécialisé en évaluation des produits, technologies et stratégies de santé innovants à destination des acteurs publics et privés des systèmes de santé :

- Etudes de recherche de l'efficacité comparative des traitements ou technologies de santé innovants (#meta analyse multi traitements)

- Etudes médico-économiques d'évaluation de l'efficience et de l'impact budgétaire des médicaments ou dispositifs médicaux (#modelisation medico economique)

- Etude médico-économique en vie réelle à partir des bases de données médico-administratives (dossier Health Data Hub (HDH), données SNDS : SNIIRAM, PMSI, CépiDC) et/ou d'études observationnelles (#etude medico economique en vie reelle)

- Ré-utilisation-valorisation statistique d'open data en santé directement accessibles, openDAMIR, openMEDIC, etc. (#open data sante).

FaLang translation system by Faboba

Actualités

New publicationSalah Ghabri PhD1, Aymeric Binard MD2, Yves-Marie Pers MD3, Franck Maunoury PhD4, J. Jaime Caro MD,CM, FRCPC, FACP567. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France. Value in Health DOI: https://doi.org/10.1016/j.jval.2019.12.003. Available online 13 February 2020.

1 Department of Economic and Public Health Evaluation, French National Authority for Health (HAS), Saint-Denis La Plaine, France 2 Department of Rheumatology, CHU de la Cavale-Blanche, Brest, France 3 Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France 4 STATESIA, Le Mans, France 5 McGill University, Montreal, QC, Canada 6 London School of Economics, London, England, UK 7 Evidera, Boston, MA, USA .

New publicationGordon Goodall1, Mark Lamotte2, Mafalda Ramos2, Franck Maunoury3, Barbora Pejchalova1, Gérard de Pouvourville4 (2019). Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients, Journal of Medical Economics, DOI: 10.1080/13696998.2018.1559600.

1 Edwards Lifesciences S.A., Route de l'Etraz 70, 1260 Nyon, Switzerland, 2 IQVIA Corporate village, Davos building, Da Vincilaan 7, 1930 Zaventem, Belgium, 3 STATESIA, 19 Boulevard Marie et Alexandre Oyon, 72100 Le Mans, France, 4 ESSEC Business School, Av. Bernard Hirsch, B.P. 50105, 95021 Cergy Pontoise Cedex, France

 

Publication Franck Maunoury1, Christian Farinetto1, Stéphane Ruckly2, Jeremy Guenezan3, Jean-Christophe Lucet4, Alain Lepape5, Julien Pascal6, Bertrand Souweine7, Olivier Mimoz3, Jean-François Timsit8(2018) Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France. PLoS ONE 13(5): e0197747. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0197747

1 Statesia, Le Mans, France, 2 ICURE Search, Outcomerea, Paris, France, 3 University Hospital of Poitiers, Emergency Department and Pre-Hospital Care, Poitiers, France, 4 Infection Control Unit, AP-HP, Bichat, University Hospital, Paris, France, 5 Department of Anaesthesiology and Critical Care Medicine, University, Hospital of Lyon-Sud, Lyon, France, 6 Adults Intensive Care Unit, Ongoing Monitoring Unit, Clermont, Ferrand University Hospital, Clermont-Ferrand, France, 7 Intensive Care Unit, Clermont Ferrand University, Hospital, Clermont-Ferrand, France, 8 Paris Diderot University - Bichat University hospital - Medical and Infectious Diseases Intensive care unit, Paris, France

Publication Maunoury F1, Clément A2, Nwankwo C3, Levy-Bachelot L2, Abergel A4, Di Martino V5, Thervet E6,7, Durand-Zaleski I8. (2018) Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. PLoS ONE 13(3). doi: 10.1371/journal.pone.0194329. eCollection 2018.

1 STATESIA, Le Mans, France, 2 MSD FRANCE, Paris, France, 3 Merck & Co., Inc., Kenilworth, New Jersey, United States of America, 4 Hepato-gastro enterology Service, CHU Estaing, Clermont-Ferrand, France, 5 Hepatology Department, Franche-Comté University and Besançon University hospital, Besançon, France, 6 HYPPARC Department, Nephrology Service, Paris Descartes University, Paris, France, 7 Georges Pompidou European Hospital (ET), Paris, France, 8 Ile-De-France URC ECO, Department of Public Health, Henri Mondor Hospital, Créteil, France

top arrow